VIGL Vigil Neuroscience
- 3.310
- -0.350-9.56%
Vigil Neuroscience News
Buy Rating Affirmed for Vigil Neuroscience Amid Anticipated Clinical Milestones and Market Expansion Opportunities
Vigil Neuroscience Shares Are Trading Higher After the Company Reported Q1 Financial Results.
Vigil Neuroscience Shares Are Trading Higher After the Company Reported Q1 Financial Results.
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersMaxCyte (NASDAQ:MXCT) shares rose 26.5% to $4.97 during Wednesday's regular session. The company's market cap stands at $519.4 million. The company's, Q1 earnings came out yesterday. Elanco Ani
Vigil Neuroscience Price Target Maintained With a $22.00/Share by Wedbush
Vigil Neuroscience Price Target Maintained With a $22.00/Share by Wedbush
Wedbush Reiterates Outperform on Vigil Neuroscience, Maintains $22 Price Target
Wedbush analyst Laura Chico reiterates Vigil Neuroscience with a Outperform and maintains $22 price target.
Vigil Neuroscience Price Target Maintained With a $24.00/Share by HC Wainwright & Co.
Vigil Neuroscience Price Target Maintained With a $24.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Reiterates Buy on Vigil Neuroscience, Maintains $24 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Vigil Neuroscience (NASDAQ:VIGL) with a Buy and maintains $24 price target.
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
Analyst Endorses Vigil Neuroscience's VGL101 With Buy Rating Amid Promising Preliminary Data and Potential Disease Modification
Buy Rating Affirmed for Vigil Neuroscience Amid Strong Clinical Progress and Robust Financial Position
Vigil Neuroscience Inc (VIGL) Q1 2024 Earnings: Challenges Persist Amid Clinical Developments
Vigil Neuroscience Q1 EPS $(0.50) Beats $(0.61) Estimate
Vigil Neuroscience (NASDAQ:VIGL) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.61) by 18.03 percent. This is a 1.96 percent increase over losses of $(
Vigil Neuroscience | 10-Q: Quarterly report
Press Release: Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update -- Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3
J.P. Morgan Securities: The Vigil Neuroscience (VIGL.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $23.00.
J.P. Morgan Securities: The Vigil Neuroscience (VIGL.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $23.00.
JMP Securities Reiterates Market Outperform on Vigil Neuroscience, Maintains $23 Price Target
JMP Securities analyst Jason Butler reiterates Vigil Neuroscience (NASDAQ:VIGL) with a Market Outperform and maintains $23 price target.
Vigil Presents Key Findings From ILLUMINATE & IGNITE Studies In ALSP At The 2024 American Academy Of Neurology Annual Meeting
Vigil Neuroscience, Inc. (NASDAQ:VIGL) today announced the presentation of multiple oral and poster presentations on the Company's lead clinical candidate iluzanebart at the 2024 American Academy of Neurology (AAN) Annual Meeting.
Buy Rating Affirmed for Vigil Neuroscience on Promising Clinical Trials and Key Data Readouts
HC Wainwright & Co. Maintains Buy on Vigil Neuroscience, Maintains $24 Price Target
HC Wainwright & Co. analyst Andrew Fein maintains Vigil Neuroscience with a Buy and maintains $24 price target.
Vigil Neuroscience Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 724.54% HC Wainwright & Co. $24 → $24 Maintains Buy 12/19/2023 37.42% Morgan Stanley $13 → $4 D
Analysis
Price Target
No Data
